Stockscreener 앱 받기
29.88
0.67%
0.20
시간 외 거래:
29.81
-0.07
-0.23%
전일 마감가:
$29.68
열려 있는:
$30.06
하루 거래량:
191.72K
Relative Volume:
0.76
시가총액:
$2.09B
수익:
-
순이익/손실:
$-198.12M
주가수익비율:
-8.8688
EPS:
-3.3691
순현금흐름:
$-159.74M
1주 성능:
+3.21%
1개월 성능:
+4.37%
6개월 성능:
+7.79%
1년 성능:
+86.87%
1일 변동 폭
$29.32
$30.61
1주일 범위
$29.09
$31.00
52주 변동 폭
$15.46
$33.33
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
29.88 | 2.07B | 0 | -198.12M | -159.74M | -3.3691 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Wolfe Research | Outperform |
| 2026-03-09 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-15 | 개시 | H.C. Wainwright | Buy |
| 2025-10-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-06-11 | 개시 | Guggenheim | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-25 | 개시 | Wedbush | Outperform |
| 2023-08-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 개시 | Bryan Garnier | Buy |
| 2022-09-13 | 재개 | JMP Securities | Mkt Outperform |
| 2022-08-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-02 | 개시 | BofA Securities | Neutral |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
모두보기
Pharvaris Nv 주식(PHVS)의 최신 뉴스
Oppenheimer maintains Pharvaris NV (PHVS) outperform recommendation - MSN
Avoiding Lag: Real-Time Signals in (PHVS) Movement - Stock Traders Daily
B of A Securities Upgrades Pharvaris N.V. (PHVS) - MSN
Pharvaris (PHVS) director sells 10,000 shares, exercises options under 10b5-1 - Stock Titan
Pharvaris (PHVS) CEO Berndt Modig updates direct and indirect share holdings - Stock Titan
[144] Pharvaris N.V. SEC Filing - Stock Titan
Pharvaris (PHVS) CEO Modig sells 2,292 shares under Rule 10b5-1 plan - Stock Titan
PHVS (NASDAQ) Form 144/A: brokered resale of 4,667 and 5,333 common shares - Stock Titan
Director Robert Glassman of Pharvaris (PHVS) sells 10,000 shares after exercising options - Stock Titan
Pharvaris (PHVS) technical ops chief sells 8,748 shares in open market - Stock Titan
Pharvaris (PHVS) CCO Souverijns sells 10,000 shares under Rule 10b5-1 plan - Stock Titan
Pharvaris N.V. (PHVS) Fell -5.23% — Is a Recovery Ahead? 2026-05-18{涓偂鍓爣棰榼 - Newser
Pharvaris N.V. (PHVS) Delivers Q1 2026 Beat — EPS $-0.59 vs $-0.73 ExpectedShare Dilution Risk - Newser
The Bull Case For Pharvaris (PHVS) Could Change Following Major Equity Raise And NDA ProgressLearn Why - simplywall.st
Viking Global affiliates hold 3.65M shares of Pharvaris (PHVS) after amendment - Stock Titan
PHVS (NASDAQ: PHVS) reports 10b5-1 sales of 23,333; 2,292 RSUs - Stock Titan
Affiliate files notice to sell 4,667 & 4,137 shares (NASDAQ: PHVS) - Stock Titan
Pharvaris N.V. (PHVS) Q4 2025 Earnings Miss: EPS $-0.72 vs $-0.63 ExpectedEPS Surprise History - Newser
Discipline and Rules-Based Execution in PHVS Response - Stock Traders Daily
Why Pharvaris Shares Are Suddenly Sliding Today - TipRanks
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Case - Yahoo Finance
Pharvaris (PHVS) CMO reports 226 shares withheld for RSU taxes - Stock Titan
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.57, Implies 49% Upside - TradingView
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.51, Implies 49% Upside - TradingView
Citizens lowers Pharvaris stock price target to $74 on valuation By Investing.com - Investing.com South Africa
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.6, Implies 49% Upside - TradingView
Citizens lowers Pharvaris stock price target to $74 on valuation - Investing.com
Pharvaris Executive Sells Common Shares Following Option Exercise - HarianBasis.co
Pharvaris Prices $115 Million Underwritten Offering of Ordinary Shares - Global Legal Chronicle
Earnings Flash (PHVS) Pharvaris Posts Q1 Per Share Loss 0.59 Euro, vs. FactSet Est of 0.71 Euro Loss - marketscreener.com
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Pharvaris (NASDAQ: PHVS) posts Q1 loss, funds pipeline into 2028 - Stock Titan
Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pharvaris earnings in focus as HAE drug candidate nears key trials By Investing.com - Investing.com South Africa
Pharvaris earnings in focus as HAE drug candidate nears key trials - Investing.com Nigeria
TradingKey - TradingKey
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 - AOL.com
Pharvaris completes $132 million share offering on Nasdaq - Investing.com UK
Pharvaris completes $132 million share offering on Nasdaq By Investing.com - Investing.com South Africa
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out - TipRanks
[6-K] Pharvaris N.V. Current Report (Foreign Issuer) | PHVS SEC FilingForm 6-K - Stock Titan
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Press Release: Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares - Moomoo
Pharvaris prices $115M stock offering - msn.com
The Bull Case For Pharvaris (PHVS) Could Change Following Dilutive US$115 Million Equity RaiseLearn Why - simplywall.st
Pharvaris Nv (PHVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pharvaris Nv 주식 (PHVS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bjork Elisabeth | Director |
May 20 '26 |
Option Exercise |
8.05 |
10,000 |
80,500 |
25,167 |
| Bjork Elisabeth | Director |
May 20 '26 |
Sale |
29.32 |
10,000 |
293,166 |
15,167 |
0.98%
0.12%
자본화:
|
볼륨(24시간):